• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The multiple roles of lysophosphatidic acid in vascular disease and atherosclerosis
Curr Opin Lipidol. 2023 Jul 28. doi: 10.1097/MOL.0000000000000890. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: To explore the multiple roles that lysophosphatidic acid (LPA) plays in vascular disease and atherosclerosis.RECENT FINDINGS: A high-fat high-cholesterol diet decreases antimicrobial activity in the small intestine, which leads to increased levels of bacterial lipopolysaccharide in the mucus of the small intestine and in plasma that increase systemic inflammation, and enhance dyslipidemia and aortic atherosclerosis. Decreasing LPA production in enterocytes reduces the impact of the diet. LPA signaling inhibit...
Source: Atherosclerosis - July 27, 2023 Category: Cardiology Authors: Arnab Chattopadhyay Srinivasa T Reddy Alan M Fogelman Source Type: research

Prospective Comparison of Plasma Biomarker and Traditional Risk Factor Profiles for Incident Isolated Atherosclerotic Disease and Incident Isolated Abdominal Aortic Aneurysm
Conclusions: The data supports the view that components of vascular inflammation and cardiovascular stress drives AAA development, whereas glycated cross-links in abdominal aortic wall tissue may have a plausible role in reducing AAA risk in individuals with DM.PMID:35097031 | PMC:PMC8790118 | DOI:10.3389/fcvm.2021.818656
Source: Atherosclerosis - January 31, 2022 Category: Cardiology Authors: Stefan Acosta Shahab Fatemi Olle Melander Gunnar Engstr öm Anders Gotts äter Source Type: research

Cilostazol Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E-Deficient Mice.
CONCLUSIONS: Cilostazol attenuated angiotensin II-induced AAA formation by its anti-inflammatory effect through phosphodiesterase III inhibition in the aortic wall. Cilostazol may be a promising new therapeutic option for AAAs. PMID: 29437572 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - February 8, 2018 Category: Cardiology Authors: Umebayashi R, Uchida HA, Kakio Y, Subramanian V, Daugherty A, Wada J Tags: Arterioscler Thromb Vasc Biol Source Type: research

Adiponectin, lipids and atherosclerosis
Purpose of review: Adiponectin is an adipokine with anti-inflammatory, antioxidant, antiatherogenic, pro-angiogenic, vasoprotective and insulin-sensitizing properties. Several factors may influence adiponectin levels, such as genetic polymorphisms, obesity / body fat distribution, diet and exercise as well as cardiovascular risk factors such as sleep deprivation and smoking as well as medications. Adiponectin has been proposed as a potential prognostic biomarker and a therapeutic target in patients with cardiometabolic diseases. Recent findings: This narrative review discusses the associations of adiponectin with obesity-...
Source: Current Opinion in Lipidology - July 14, 2017 Category: Lipidology Tags: HYPERLIPIDAEMIA AND CARDIOVASCULAR DISEASE: Edited by Paul N. Durrington Source Type: research